PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights
PosiFunda · Fundamentals

Delcath Systems, Inc.

PosiFunda Ratios Only on PositoAI

PositoAI's own ratios from Delcath Systems, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.

What stands out

  • Debt Due Cover Ratio: Debt due within a year is covered 222.9 times by its yearly operating cash. Higher than almost all Healthcare companies in United States.

Cash quality

Profit Cash Ratio

—

Loss-making or profit too small

Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.

Self-Funding Ratio

-12.7×

Over the last 3 years operating cash was negative while the company kept spending on investment (capex).

Lower than 54% of Healthcare companies in United States.

Cash Locked Ratio

$24

For every $100 of sales, $24 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $13 tied up three years earlier.

More money tied up than 51% of Healthcare companies in United States.

Growth quality

Steadiness Ratio

2/3 · 2/3

Sales grew in 2 of the last 3 years; profit grew in 2 of 3.

Steadier than 69% of Healthcare companies in United States.

Growth Efficiency Ratio

$48

Sales grew 3,035% in 3 years; of every extra $100 of sales, $48 became extra profit.

Higher than 69% of Healthcare companies in United States.

Asset Productivity Ratio

+3035% / +592%

In 3 years sales changed by +3035% while total assets changed by +592%. Sales grew faster than assets.

Balance-sheet strength

Debt Due Cover Ratio

222.9×

Debt due within a year is covered 222.9 times by its yearly operating cash.

Higher than almost all Healthcare companies in United States.

Cash Cushion Ratio

+18%

Cash, after subtracting all debt, equals 18% of its market value (net cash).

Higher than 60% of Healthcare companies in United States.

Tangible Assets Ratio

—

Data incomplete

Tangible Net Worth Ratio

—

Data incomplete

Shareholders

Shareholder Slice Ratio

+245%

Share count rose 245% in 3 years, so each share's slice of the company became smaller.

Bigger rise in share count than 80% of Healthcare companies in United States.

Standard fundamentals

P/E, P/B, ROE, debt, growth and more (13)

Delcath Systems, Inc. owes $0.12 for every $1 it owns. Delcath Systems, Inc. returned to profit in the year to Dec 2025, after a loss the year before.

Compared with Healthcare companies in United States · latest annual results Dec 2025.

P/E ratio

1475.0

Investors pay $1475.0 for every $1 of Delcath Systems, Inc.'s yearly profit, higher than almost all Healthcare companies in United States.

P/B ratio

4.22

The share price is 4.22 times Delcath Systems, Inc.'s book value per share, higher than 67% of Healthcare companies in United States.

Market cap

$512 M

The total market value of all of Delcath Systems, Inc.'s shares at today's price (share price × number of shares), larger than 55% of Healthcare companies in United States. PosiCap size class: Mini Cap.

Net worth (book value)

$121 M

What Delcath Systems, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).

Book value per share

$3.49

Net worth divided by the number of shares. The share price of $14.75 is 4.2 times this, which is the P/B above.

Return on equity (ROE)

0.5%

Delcath Systems, Inc. earned 0.5% on its shareholders' money over the last year, higher than 76% of Healthcare companies in United States.

Owes vs Owns

0.12×

Delcath Systems, Inc. owes $0.12 for every $1 it owns (low), lower than 84% of Healthcare companies in United States.

Dividend yield

None

Delcath Systems, Inc. does not currently pay a dividend.

Revenue growth

+129%

Revenue rose 129% in the year to Dec 2025, and grew 215% a year on average over 3 years.

Profit growth

Back to profit

Delcath Systems, Inc. returned to profit in the year to Dec 2025, after a loss the year before.

Profit margin

3.2%

Delcath Systems, Inc. keeps $3 of every $100 of revenue as net profit.

Cash quality

8.3×

Cash from Delcath Systems, Inc.'s business was 8.3× its reported profit in the year to Dec 2025 — its profit turned into cash.

Cash vs debt

Net cash

Delcath Systems, Inc. held $90 M more cash than debt (net cash) at Dec 2025.

Questions

What is Delcath Systems, Inc.'s P/E ratio?

Investors pay $1475.0 for every $1 of Delcath Systems, Inc.'s yearly profit, higher than almost all Healthcare companies in United States.

How is P/B calculated on PositoAI?

P/B is market cap divided by net worth from the latest balance sheet. For Delcath Systems, Inc.: $512 M ÷ $121 M (30 Jun 2026) = 4.2.

What is Delcath Systems, Inc.'s return on equity?

Delcath Systems, Inc. earned 0.5% on its shareholders' money over the last year, higher than 76% of Healthcare companies in United States.

How much does Delcath Systems, Inc. owe compared with what it owns?

Delcath Systems, Inc. owes $0.12 for every $1 it owns (low), lower than 84% of Healthcare companies in United States.

Does Delcath Systems, Inc. pay a dividend?

No. Delcath Systems, Inc. does not currently pay a dividend.

Is Delcath Systems, Inc.'s revenue growing?

Revenue rose 129% in the year to Dec 2025, and grew 215% a year on average over 3 years.

Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.